Meeting with Companies in Chungbuk Advanced Regenerative Bio Special Zone
Participating Companies Call for Reforms to Regulations on Domestic Clinical Trials and Commercialization
Lee: "Four Sectors, Including Pharmaceuticals and Bio, Selected; Organization to Be Established"

Lee Soyoung, Minister of SMEs and Startups, said on October 16, "We have selected four major industrial sectors in which SMEs and venture companies can thrive, and pharmaceuticals and bio is one of them." She added, "We also plan to establish an organization to identify the Ministry's role as we focus on these sectors."


Lee made the remarks that morning at a meeting with companies participating in the Chungbuk Advanced Regenerative Bio Global Innovation Regulatory Free Zone, held at the headquarters of Organoid Science in Cheongju, Chungbuk. The meeting was organized to hear companies' concerns about the project. A total of 13 people attended, including Minister Lee, Yang Gwangseok, head of the Special Zone Innovation Planning Group, and representatives of participating companies.


The Chungbuk Advanced Regenerative Bio Global Innovation Special Zone is a project that supports the demonstration and commercialization of advanced regenerative bio technologies using cells and genes. A total of 23 companies, six hospitals and six related organizations are participating, centered on Osong in Cheongju.

Lee Soyoung, Minister of SMEs and Startups, delivers opening remarks at a meeting held on the 16th at the headquarters of Organoid Science in Cheongju, North Chungcheong Province. Ministry of SMEs and Startups.

Lee Soyoung, Minister of SMEs and Startups, delivers opening remarks at a meeting held on the 16th at the headquarters of Organoid Science in Cheongju, North Chungcheong Province. Ministry of SMEs and Startups.

View original image

At the meeting, regulatory issues hindering the commercialization of advanced regenerative bio technologies developed in Korea emerged as a key topic. In particular, participants pointed to the uncertainty of Korea's approval process, which has led some companies to pursue demonstrations or commercialization in Japan. Although Korea has allowed advanced regenerative medical treatments in stages since February 2025, the system is still in its early stages, they said. Japan, by contrast, has operated a conditional and time-limited approval system for regenerative medicine since 2014. Seven companies participating in the special zone have set up operations at Shonan iPark in Japan and are pursuing local demonstrations.


Yoo Jongman, CEO of Organoid Science, also cited uncertainty in Korea's approval process and institutional constraints as reasons for the company's entry into Japan. Organoid Science is pursuing clinical trials in Japan for a regenerative therapy based on intestinal organoids developed in Korea.


As measures to improve the system, Yoo proposed three steps: (1) facilitating entry into clinical research and expanding the use of treatments; (2) allowing overseas demonstration data to be used in domestic approval applications; and (3) expanding companies' participation in manufacturing and commercialization after the research phase. He also called for support for testing methods that replace animal experiments in drug development. With animal-free testing methods using organoids and other technologies expanding worldwide, he warned that Korean drug developers could lose their sovereignty over drug development if they are unable to use these methods.


Some participants also argued that regulatory reform in advanced regenerative bio should be approached as a matter of "health security." Hwang Junseong, CEO of Kyupikeu Bio, cited the COVID-19 vaccine as an example and stressed the importance of securing domestic bio technologies and industrial competitiveness as competition for technological dominance intensifies.



Minister Lee said, "I will make an effort to communicate more with companies and work closely with relevant ministries so that we can reflect the points raised today."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing